Taiwan

Abstract

This chapter presents an overview of how decision-making processes for the reimbursement for new medicines have evolved in Taiwan over the last 20 years and how patient involvement has developed since it began in 2015. It outlines patient participation in the HTA programme that informs medicine reimbursement. It shows how Taiwan is encouraging patient participation in HTA via online submissions, participation in committee meetings and educational events and continues to develop its participation processes. The chapter highlights the challenges of patient participation in a setting where patient groups have little experience of engagement in policy. It also points to the need for guidance on using patient-based evidence in HTA and the potential value of resources that can be adapted to meet local needs and support HTA bodies developing patient involvement programmes.